Alpha-9 Theranostics

Executive Summary

Alpha-9 Theranostics is a preclinical-stage biotechnology company headquartered in San Diego, focused on developing targeted radiopharmaceuticals for cancer imaging and therapy. The company’s platform links tumor-targeting peptides to radioactive isotopes to create paired diagnostic and therapeutic agents, enabling a theranostic approach that combines diagnosis and treatment monitoring. With $75 million raised since its founding in 2020, Alpha-9 is advancing a pipeline initially targeting prostate cancer and other solid tumors. The company aims to address limitations of current radiopharmaceuticals by improving tumor specificity, reducing off-target toxicity, and enabling real-time assessment of therapeutic response. The theranostics market is expanding rapidly, driven by the success of agents like Lutathera and Pluvicto, and Alpha-9’s differentiated peptide-based platform could capture significant share if clinical validation is achieved. However, as a preclinical company, Alpha-9 faces risks common to early-stage radiopharmaceutical development, including manufacturing complexity, regulatory hurdles, and competition from established players. Near-term value will depend on generating compelling preclinical data, securing IND clearance for lead candidates, and establishing partnerships to finance clinical trials. The company’s strong funding base and experienced management team provide a solid foundation, but investors should monitor upcoming milestones closely for signs of platform validation.

Upcoming Catalysts (preview)

• Q3 2026Preclinical efficacy data for lead candidate in prostate cancer models70% success
• Q1 2027IND filing for lead diagnostic/therapeutic pair60% success
• Q4 2026Partnership or licensing deal for manufacturing or co-development50% success